Principales publications du centre en lien avec maladies rares (liste articles 10 ans)

- Dendooven A, Vandendriessche A, Koshy PJ, Timmermans F, Speeckaert M, Kint N, Van Aelst L, Vekemans MC, Meuleman N, Pouleur AC, Bondue A, Droogmans S, Debonnaire P, De Bleecker J, Van Craenenbroeck A, Gallardo R, Schymkowitz J, Rousseau F, Impens F, Devos S, Delforge M. Belgian recommendations for tissue diagnosis of amyloidosis. Acta Clin Belg. 2026 Apr 27:1-14. doi: 10.1080/17843286.2026.2660739. Epub ahead of print. PMID: 42043894.
- Lancellotti P, Cosyns B, Cools F, Gerber B, Bondue A, Robyns T, Willems R. Rare cardiovascular diseases: diagnostic progress and organizational gaps: the Belgian perspective. Acta Cardiol. 2026 May;81(3):424-428. doi: 10.1080/00015385.2026.2645456. Epub 2026 Mar 17. PMID: 41843402.
- Desai MY, Owens A, Garcia-Pavia P, Abraham T, Nissen SE, Chevalier P, Wang A, De Souza J, Bach R, Bondue A, Gong Z, Aronson R, Florea V, Olivotto I; ODYSSEY-HCM Investigators. Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Baseline Characteristics, Drug Exposure, and Outcomes in an Exploratory Analysis From ODYSSEY-HCM. J Am Coll Cardiol. 2026 Mar 16:S0735-1097(26)00326-8. doi: 10.1016/j.jacc.2025.12.092. Epub ahead of print. PMID: 41879580.
- Desai MY, Owens AT, Abraham T, Olivotto I, Garcia-Pavia P, Lopes RD, Elliott P, Fernandes F, Verheyen N, Maier L, Meder B, Azevedo O, Kitaoka H, Wolski K, Wang Q, Jaber W, Mitchell L, Myers J, Rano T, Gong Z, Zhong Y, Carter-Bonanza S, Florea V, Aronson R, Nissen SE; ODYSSEY-HCM Investigators. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025 Sep 11;393(10):961-972. doi: 10.1056/NEJMoa2505927. Epub 2025 Aug 30. PMID: 40888717.
- Singh A, Wyatt J, Théaudin M, Karam C, Kasper D, Streubel B, Frascello K, Bondue A. Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis. J Clin Med. 2025 Sep 26;14(19):6821. doi: 10.3390/jcm14196821. PMID: 41095902; PMCID: PMC12524576.
- Maurer MS, Berk JL, Damy T, Sheikh FH, González-Costello J, Morbach C, Delgado D, Bondue A, Azevedo O, Poulsen SH, Jankowska EA, Yang L, Bender S, Eraly SA, Jay PY, Vest J, Fontana M. Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B. J Am Coll Cardiol. 2025 Aug 12;86(6):459-475. doi: 10.1016/j.jacc.2025.04.055. PMID: 40769675.
- Kääb S, Bondue A. An update on the ESC Council on Cardiovascular Genomics: out from the niche into the open. Eur Heart J. 2025 May 14;46(19):1784-1786. doi: 10.1093/eurheartj/ehaf068. PMID: 40079516.
- Delstanche S, Claeys KG, De Bleecker, Remiche G, Troisfontaines P, Van Parys V, Bondue A. Phenotype variability and therapeutic response to Patisiran in patients with hereditary transthyretin amyloidosis: a Belgian real-world experience. Acta Clin Belg. 2024 Dec;79(6):393-402. doi: 10.1080/17843286.2025.2464971. Epub 2025 Feb 19. PMID: 39970316.
- Gonçalves T, Garot J, Toupin S, Bousson V, Sanguineti F, Akodad M, Duhamel S, Champagne S, Neylon A, Unterseeh T, Hovasse T, Hamzi L, Unger A, Florence J, Mirailles R, Bondue A, Dillinger JG, Henry P, Garot P, Pezel T. Prognostic impact of late gadolinium enhancement granularity in non-ischemic dilated cardiomyopathy. Eur Radiol. 2025 Aug;35(8):4699-4710. doi: 10.1007/s00330-025-11404-8. Epub 2025 Feb 8. PMID: 39920302.

- Elliott P, Schunkert H, Bondue A, Behr E, Carrier L, Van Duijn C, García-Pavía P, van der Harst P, Kavousi M, Loeys B, Rocha Lopes L, Pinto Y, Di Toro A, Thum T, Kääb S, Urtis M, Arbustini E. Integration of genetic testing into diagnostic pathways for cardiomyopathies: a clinical consensus statement by the ESC Council on Cardiovascular Genomics. Eur Heart J. 2025 Jan 21;46(4):344-353. doi: 10.1093/eurheartj/ehae747. PMID: 39673718.
- Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, Damy T, Garcia-Pavia P, Taubel J, Solomon SD, Sheikh FH, Tahara N, González-Costello J, Tsujita K, Morbach C, Pozsonyi Z, Petrie MC, Delgado D, Van der Meer P, Jabbour A, Bondue A, Kim D, Azevedo O, Hvitfeldt Poulsen S, Yilmaz A, Jankowska EA, Algalarrondo V, Slugg A, Garg PP, Boyle KL, Yureneva E, Silliman N, Yang L, Chen J, Eraly SA, Vest J, Maurer MS; HELIOS-B Trial Investigators. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2025 Jan 2;392(1):33-44. doi: 10.1056/NEJMoa2409134. Epub 2024 Aug 30. PMID: 39213194.
- Paelinck BP, Bondue A, Robyns T, Eyskens F. Left ventricular hypertrophy: do not forget Fabry disease. Diagnostic work-up and differential diagnosis. Acta Cardiol. 2024 Aug;79(6):642-649. doi: 10.1080/00015385.2024.2346873. Epub 2024 Jun 13. PMID: 38869089.
- Goldman M, Bondue A, Cogan E. Inflammation, infection, and cardiovascular risk. Lancet. 2024 Mar 16;403(10431):1023. doi: 10.1016/S0140-6736(23)02877-5. PMID: 38492939.
- Chomette L, Migeotte I, Dewachter C, Vachiery JL, Smits G, Bondue A. Early-onset and severe pulmonary arterial hypertension due to a novel compound heterozygous association of rare *VHL*mutations: A case report and review of existing data. Pulm Circ. 2022 Apr 1;12(2):e12052. doi: 10.1002/pul2.12052. PMID: 35734542; PMCID: PMC9190294.
- Bondue A, Carpentier C, Roufosse F. Hypereosinophilic syndrome: considerations for the cardiologist. Heart. 2022 Feb;108(3):164-171. doi: 10.1136/heartjnl-2020-317202. Epub 2021 Jun 25. PMID: 34172539.
- Hemelsoet D, De Keyser J, Van Heuverswyn F, Willems R, Vandekerckhove H, Bondue A, de Asmundis C, Saenen J, Van de Walle S, Godart P, Kampmann C, Stepman H, Poppe B, Terryn W. Screening for Fabry Disease in Male Patients With Arrhythmia Requiring a Pacemaker or an Implantable Cardioverter-Defibrillator. Circulation. 2021 Feb 23;143(8):872-874. doi: 10.1161/CIRCULATIONAHA.120.051400. Epub 2021 Feb 22. PMID: 33617311.
- Campens L, Baris L, Scott NS, Broberg CS, Bondue A, Jondeau G, Grewal J, Johnson MR, Hall R, De Backer J, Roos-Hesselink JW; ROPAC investigators group. Pregnancy outcome in thoracic aortic disease data from the Registry Of Pregnancy And Cardiac disease. Heart. 2021 Nov;107(21):1704-1709. doi: 10.1136/heartjnl-2020-318183. Epub 2021 Jan 19. PMID: 33468574; PMCID: PMC8522458.
- De Backer J, Bondue A, Budts W, Evangelista A, Gallego P, Jondeau G, Loeys B, Peña ML, Teixido-Tura G, van de Laar I, Verstraeten A, Roos Hesselink J. Genetic counselling and testing in adults with congenital heart disease: A consensus document of the ESC Working Group of Grown-Up Congenital Heart Disease, the ESC Working Group on Aorta and Peripheral Vascular Disease and the European Society of Human Genetics. Eur J Prev Cardiol. 2020 Sep;27(13):1423-1435. doi: 10.1177/2047487319854552. Epub 2019 Jun 11. PMID: 31184212.
- Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, Kubanek M, Wojakowski W, Jensen MK, Gimeno-

Blanes J, Afshar K, Myers J, Hegde SM, Solomon SD, Sehnert AJ, Zhang D, Li W, Bhattacharya M, Edelberg JM, Waldman CB, Lester SJ, Wang A, Ho CY, Jacoby D; EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29. Erratum in: Lancet. 2020 Sep 12;396(10253):758. doi: 10.1016/S0140-6736(20)31872-9. PMID: 32871100.

- Descamps OS, Van Caenegem O, Hermans MP, Balligand JL, Beauloye C, Bondue A, Carlier S, Castermans E, Chenot F, Claeys M, De Block C, de Leener A, De Meester A, Demeure F, De Raedt H, Desmet W, Elegeert I, Guillaume M, Hoffer E, Kacenelenbogen R, Lancellotti P, Langlois M, Leone A, Mertens A, Paquot N, Vanakker O, Vanoverschelde JL, Verhaegen A, Vermeersch P, Wallemacq C, Rietzschel E; Belgian Atherosclerosis Society/Belgian Lipid Club (BAS/BLC), the Belgian Society of Cardiology (BSC) and the Royal Belgian Society of Laboratory Medicine (RBSLM). A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy). Atherosclerosis. 2018 Oct;277:369-376. doi: 10.1016/j.atherosclerosis.2018.05.037. PMID: 30270073.
- Bondue A, Arbustini E, Bianco A, Ciccarelli M, Dawson D, De Rosa M, Hamdani N, Hilfiker-Kleiner D, Meder B, Leite-Moreira AF, Thum T, Tocchetti CG, Varricchi G, Van der Velden J, Walsh R, Heymans S. Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovasc Res. 2018 Aug 1;114(10):1287-1303. doi: 10.1093/cvr/cvy122. PMID: 29800419; PMCID: PMC6054212.
- Marston NA, Bergmark BA, Alexander VJ, et al.; CORE-TIMI 72a and CORE2-TIMI 72b Investigators. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. N Engl J Med. 2026;394(5):429-441. doi:10.1056/NEJMoa2512761. PMID: 41211918.
- Descamps OS, Rietzschel E, Laporte A, et al. Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy. *Acta Cardiol.* 2021;76(3):227-235.
- Marston NA, Bergmark BA, Alexander VJ, et al.; CORE-TIMI 72a and CORE2-TIMI 72b Investigators. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. *N Engl J Med.* 2026;394(5):429-441. doi:10.1056/NEJMoa2512761. PMID: 41211918.
- Descamps OS, Rietzschel E, Laporte A, et al. Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy. *Acta Cardiol.* 2021;76(3):227-235. doi:10.1080/00015385.2020.1820683. PMID: 32964780.